Terns Pharmaceuticals Inc is a biotechnology business based in the US. Terns Pharmaceuticals Inc shares (TERN) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $3.30 – the same closing value as a week prior. Terns Pharmaceuticals Inc employs 59 staff and has a trailing 12-month revenue of around $1 million.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $3.30 |
|---|---|
| 52-week range | $1.87 - $11.40 |
| 50-day moving average | $3.05 |
| 200-day moving average | $5.89 |
| Wall St. target price | $18.94 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.12 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $3.3 from 2025-05-05
| 1 week (2025-04-29) | 6.11% |
|---|---|
| 1 month (2025-04-07) | 65.00% |
| 3 months (2025-02-07) | -26.34% |
| 6 months (2024-11-07) | -53.26% |
| 1 year (2024-05-07) | -42.71% |
|---|---|
| 2 years (2023-05-05) | -73.52% |
| 3 years (2022-05-06) | 110.19% |
| 5 years (2020-05-03) | N/A |
| Revenue TTM | $1 million |
|---|---|
| Gross profit TTM | $1 million |
| Return on assets TTM | -20.13% |
| Return on equity TTM | -29.56% |
| Profit margin | 0% |
| Book value | $3.97 |
| Market Capitalization | $305.5 million |
TTM: trailing 12 months
We're not expecting Terns Pharmaceuticals Inc to pay a dividend over the next 12 months.
You may also wish to consider:
Terns Pharmaceuticals Inc's shares were split on a 1000:50 basis on 3 November 2013 . So if you had owned 50 shares the day before before the split, the next day you'd have owned 1000 shares. This wouldn't directly have changed the overall worth of your Terns Pharmaceuticals Inc shares – just the quantity. However, indirectly, the new 95% lower share price could have impacted the market appetite for Terns Pharmaceuticals Inc shares which in turn could have impacted Terns Pharmaceuticals Inc's share price.
Over the last 12 months, Terns Pharmaceuticals Inc's shares have ranged in value from as little as $1.865 up to $11.4. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Terns Pharmaceuticals Inc's is -0.141. This would suggest that Terns Pharmaceuticals Inc's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Terns Pharmaceuticals Inc has bucked the trend.
To put Terns Pharmaceuticals Inc's beta into context you can compare it against those of similar companies.
Terns Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity, as well as TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California. .
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
These are the stocks to buy when you don’t have much to spend.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Some of the best stock trading apps for beginners include SoFi, Robinhood, Public, Stash, Opto and more. Compare your options here.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Compare the 7 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .